#1 Clinical Trials Search in Europe

Falbikitug

A new clinical trial is investigating the use of Falbikitug (AZD0171) in combination with other treatments for patients with early-stage, resectable non-small cell lung cancer (NSCLC). This Phase II study aims to evaluate the effectiveness and safety of using Falbikitug as part of neoadjuvant (before surgery) and adjuvant (after surgery) treatment approaches. The trial focuses on patients with Stage II to IIIB NSCLC and seeks to improve outcomes for those diagnosed with this challenging disease.

Table of Contents

What is FALBIKITUG?

FALBIKITUG, also known as AZD0171, is a new medication being studied for the treatment of early-stage non-small cell lung cancer (NSCLC)[1]. It is a type of drug called a humanized monoclonal antibody, which is a laboratory-made protein that mimics the immune system’s ability to fight harmful cells[1]. Specifically, FALBIKITUG targets a protein called LIF (Leukemia Inhibitory Factor), which is part of a family of proteins known as interleukin 6 family cytokines[1].

Medical Conditions Treated

FALBIKITUG is being investigated for the treatment of resectable, early-stage (II to IIIB) non-small cell lung cancer[1]. This means it’s intended for patients who have lung cancer that:

  • Is classified as non-small cell lung cancer (NSCLC), which is the most common type of lung cancer
  • Is in an early stage (stage II to IIIB), meaning the cancer has not spread widely throughout the body
  • Is considered resectable, which means it can potentially be removed through surgery

How FALBIKITUG Works

While the exact mechanism of action is not fully described in the provided information, we can infer some details based on what we know about FALBIKITUG:

  1. As a monoclonal antibody, it’s designed to target specific proteins in the body[1].
  2. It targets the LIF protein, which is involved in various cellular processes and may play a role in cancer growth[1].
  3. By targeting LIF, FALBIKITUG may help to slow down or stop the growth of cancer cells, potentially making tumors easier to remove surgically or more responsive to other treatments[1].

Clinical Trial Details

FALBIKITUG is currently being studied in a Phase II clinical trial called NeoCOAST-2[1]. Here are some key details about the trial:

  • It’s an open-label, multicentre, randomized study, which means participants and researchers know which treatment is being given, it’s conducted at multiple hospitals or clinics, and participants are randomly assigned to different treatment groups[1].
  • The study is looking at both neoadjuvant treatment (given before surgery) and adjuvant treatment (given after surgery)[1].
  • The main goals of the study are to assess how well the treatment works in shrinking tumors before surgery and to evaluate its safety and tolerability[1].
  • Secondary goals include looking at how the treatment affects survival rates, how feasible it is for patients to proceed to surgery after treatment, and how the drug behaves in the body[1].

Eligibility Criteria

To participate in the clinical trial for FALBIKITUG, patients must meet certain criteria[1]. Some key eligibility factors include:

  • Having newly diagnosed NSCLC that is resectable and in stage IIA to IIIB
  • Being in good overall health (WHO or ECOG performance status of 0 or 1)
  • Having adequate organ and bone marrow function
  • Being able to provide tumor samples for testing
There are also several factors that would exclude a patient from participating, such as having certain genetic mutations, severe heart problems, or autoimmune disorders[1].

Potential Benefits

While it’s important to note that FALBIKITUG is still in the research phase and its benefits are not yet fully known, the clinical trial aims to assess several potential benefits[1]:

  • Shrinking tumors before surgery (measured as pathological complete response or pCR)
  • Improving the success rate of surgery
  • Extending the time patients live without their cancer returning or getting worse (event-free survival and disease-free survival)
  • Increasing overall survival rates

Safety and Side Effects

As FALBIKITUG is still in clinical trials, its full safety profile is not yet established. The NeoCOAST-2 study is specifically designed to evaluate the safety and tolerability of the drug[1]. This will involve monitoring:

  • Adverse events (side effects)
  • Vital signs
  • Clinical laboratory parameters
Patients considering participating in the clinical trial should discuss potential risks and side effects with their healthcare provider and the research team[1].

Aspect Details
Study Type Phase II, open-label, multicentre, randomised
Target Population Patients with resectable, early-stage (II to IIIB) non-small cell lung cancer
Main Objectives Assess antitumor activity of neoadjuvant treatment and safety/tolerability of neoadjuvant/adjuvant treatment
Primary Endpoints Pathological Complete Response (pCR), Safety and tolerability
Secondary Endpoints Event-free survival, Disease-free survival, Feasibility of surgery, Objective response rate, Overall survival
Key Inclusion Criteria Newly diagnosed NSCLC (Stage IIA to IIIB), Good performance status, Adequate organ function
Key Exclusion Criteria Certain genetic mutations, Autoimmune disorders, Prior immunotherapy exposure
Treatment Approach Neoadjuvant therapy followed by surgery and adjuvant therapy

FAQ

  • What is Falbikitug and how does it work? Falbikitug (AZD0171) is a humanized monoclonal antibody that targets LIF (Leukemia Inhibitory Factor), which is part of the interleukin 6 family of cytokines. It works by modulating the immune system to help fight cancer cells.
  • Who is eligible for this clinical trial? The trial is for patients with newly diagnosed, resectable non-small cell lung cancer (NSCLC) at stages IIA to IIIB. Participants must have good overall health status and adequate organ function. However, patients with certain genetic mutations or autoimmune disorders are not eligible.
  • What does the treatment involve? The treatment involves receiving Falbikitug along with other drugs before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy). The exact combination and schedule will be determined by the study protocol.
  • What are the main goals of this clinical trial? The primary goals are to assess the anti-tumor activity of the neoadjuvant treatment by measuring the pathological complete response (pCR) and to evaluate the safety and tolerability of both neoadjuvant and adjuvant treatments.
  • How will the effectiveness of the treatment be measured? The effectiveness will be measured through various endpoints, including pathological complete response (pCR), event-free survival (EFS), disease-free survival (DFS), objective response rate (ORR), and overall survival (OS). The study will also look at the feasibility of performing surgery after neoadjuvant treatment.

Ongoing Clinical Trials on Falbikitug

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

Glossary

  • Falbikitug (AZD0171): A humanized monoclonal antibody that targets LIF (Leukemia Inhibitory Factor) in the interleukin 6 family of cytokines, used in cancer treatment.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that includes several subtypes, such as adenocarcinoma and squamous cell carcinoma. It is the most common form of lung cancer.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually before surgery, to shrink the tumor and make it easier to remove.
  • Adjuvant therapy: Additional treatment given after the primary treatment (usually surgery) to lower the risk of cancer returning.
  • Pathological Complete Response (pCR): The absence of any viable cancer cells in the removed tumor tissue and lymph nodes after treatment, as determined by microscopic examination.
  • Event-free survival (EFS): The length of time after treatment during which a patient remains free of certain complications or events related to their disease.
  • Disease-free survival (DFS): The amount of time after treatment during which no sign of cancer is found.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Circulating tumor DNA (ctDNA): Fragments of DNA from cancer cells that can be found in the blood, used to monitor cancer progression or treatment response.
  • PD-L1 expression: The presence of a protein called Programmed Death-Ligand 1 on cancer cells, which can help predict response to certain immunotherapy treatments.

References

  1. http://clinicaltrials.eu/trial/study-of-volrustomig-and-drug-combination-for-patients-with-early-stage-resectable-non-small-cell-lung-cancer/